Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLG CML8 imatinib discontinuation in chronic phase CML with stable molecular remission
ACTRN12606000118505Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in chronic myelogenous leukemia (CML), sponsored by Australasian Leukaemia & Lymphoma Group. Started Aug 2006; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12606000118505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000118505.